Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Clinical Trials Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Clinical Trials Market
5.1. Covid-19: Clinical Trials Industry Impact
5.2. Clinical Trials Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Clinical Trials Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Clinical Trials Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Clinical Trials Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing number of clinical trials in developing regions
6.1.2. Market Restraints
6.1.2.1. Rigorous guidelines
6.1.3. Market Opportunities
6.1.3.1. Increasing demand for advanced treatments such as personalized medicines
6.1.3.2. Technological advancements
Chapter 7. Global Clinical Trials Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Clinical Trials Market Revenue by Market Players (2018 -2022)
7.1.1.2. Clinical Trials Market Revenue Market Share by Market Players (2018 -2022)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Phase Portfolio Expansion, Geographic Expansion, Phase Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Clinical Trials Market, By Phase
8.1. Clinical Trials Market, by Phase, 2020 - 2032
8.1.1. Phase 1
8.1.1.1. Market Revenue and Forecast (2020 - 2032)
8.1.2. Phase 2
8.1.2.1. Market Revenue and Forecast (2020 - 2032)
8.1.3. Phase 3
8.1.3.1. Market Revenue and Forecast (2020 - 2032)
8.1.4. Phase 4
8.1.4.1. Market Revenue and Forecast (2020 - 2032)
Chapter 9. Global Clinical Trials Market, By Study Design
9.1. Clinical Trials Market, by Study Design, 2020 - 2032
9.1.1. Observational
9.1.1.1. Market Revenue and Forecast (2020 - 2032)
9.1.2. Interventional
9.1.2.1. Market Revenue and Forecast (2020 - 2032)
9.1.3. Expanded Access
9.1.3.1. Market Revenue and Forecast (2020 - 2032)
Chapter 10. Global Clinical Trials Market, By Indication
10.1. Clinical Trials Market, by Indication, 2020 - 2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020 - 2032)
10.1.2. Autoimmune/Inflammation
10.1.2.1. Market Revenue and Forecast (2020 - 2032)
10.1.3. Diabetes
10.1.3.1. Market Revenue and Forecast (2020 - 2032)
10.1.4. Central Nervous System
10.1.4.1. Market Revenue and Forecast (2020 - 2032)
10.1.5. Cardiovascular
10.1.5.1. Market Revenue and Forecast (2020 - 2032)
10.1.6. Pain Management
10.1.7. Market Revenue and Forecast (2020 - 2032)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2020 - 2032)
Chapter 11. Global Clinical Trials Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue Forecast by Phase(2020 - 2032)
11.1.2. Market Revenue Forecast by Study Design(2020 - 2032)
11.1.3. Market Revenue Forecast by Indication (2020 - 2032)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2020 - 2032)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2020 - 2032)
11.2. Europe
11.2.1. Market Revenue Forecast by Phase (2020 - 2032)
11.2.2. Market Revenue Forecast by Study Design (2020 - 2032)
11.2.3. Market Revenue Forecast by Indication (2020 - 2032)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2020 - 2032)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2020 - 2032)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2020 - 2032)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2020 - 2032)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Phase (2020 - 2032)
11.3.2. Market Revenue Forecast by Study Design (2020 - 2032)
11.3.3. Market Revenue Forecast by Indication (2020 - 2032)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2020 - 2032)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2020 - 2032)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2020 - 2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2020 - 2032)
11.4. LATAM
11.4.1. Market Revenue Forecast by Phase (2020 - 2032)
11.4.2. Market Revenue Forecast by Study Design (2020 - 2032)
11.4.3. Market Revenue Forecast by Indication (2020 - 2032)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2020 - 2032)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2020 - 2032)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Phase (2020 - 2032)
11.5.2. Market Revenue Forecast by Study Design (2020 - 2032)
11.5.3. Market Revenue Forecast by Indication (2020 - 2032)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2020 - 2032)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2020 - 2032)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2020 - 2032)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2020 - 2032)
Chapter 12. Company Profiles
12.1. Parexel
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Phase Portfolio Analysis
12.1.2.1. Product Details, Specification, Indication
12.1.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.1.4. Recent Developments and Strategies
12.2. IQVIA
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Phase Portfolio Analysis
12.2.2.1. Product Details, Specification, Indication
12.2.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.2.4. Recent Developments and Strategies
12.3. Charles River Laboratory
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Phase Portfolio Analysis
12.3.2.1. Product Details, Specification, Indication
12.3.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.3.4. Recent Developments and Strategies
12.4. Omnicare
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Phase Portfolio Analysis
12.4.2.1. Product Details, Specification, Indication
12.4.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.4.4. Recent Developments and Strategies
12.5. Kendle
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Phase Portfolio Analysis
12.5.2.1. Product Details, Specification, Indication
12.5.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.5.4. Recent Developments and Strategies
12.6. Chiltern
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Phase Portfolio Analysis
12.6.2.1. Product Details, Specification, Indication
12.6.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.6.4. Recent Developments and Strategies
12.7. Pharmaceutical Product Development, LLC
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Phase Portfolio Analysis
12.7.2.1. Product Details, Specification, Indication
12.7.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.7.4. Recent Developments and Strategies
12.8. Company 8
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Phase Portfolio Analysis
12.8.2.1. Product Details, Specification, Indication
12.8.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.8.4. Recent Developments and Strategies
12.9. Company 9
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Phase Portfolio Analysis
12.9.2.1. Product Details, Specification, Indication
12.9.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Phase Portfolio Analysis
12.10.2.1. Product Details, Specification, Indication
12.10.3. Revenue, Price, and Gross Margin (2020 - 2022)
12.10.4. Recent Developments and Strategies
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client